First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Update

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 134,463 shares, a drop of 41.9% from the August 15th total of 231,413 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily volume of 130,940 shares, the short-interest ratio is currently 1.0 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Up 1.4%

Shares of NASDAQ FTXH opened at $41.40 on Friday. First Trust Nasdaq Pharmaceuticals ETF has a fifty-two week low of $27.30 and a fifty-two week high of $42.87. The business has a 50 day moving average price of $40.18 and a two-hundred day moving average price of $36.79. The firm has a market cap of $1.07 billion, a PE ratio of 14.51 and a beta of 0.46.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, June 25th were paid a dividend of $0.092 per share. This represents a $0.37 annualized dividend and a yield of 0.9%. This is a boost from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.06. The ex-dividend date was Thursday, June 25th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Marshall Investment Management LLC acquired a new stake in First Trust Nasdaq Pharmaceuticals ETF in the fourth quarter worth approximately $1,377,000. Nilsine Partners LLC boosted its stake in First Trust Nasdaq Pharmaceuticals ETF by 3.5% during the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock valued at $1,071,000 after purchasing an additional 937 shares in the last quarter. Compass Financial Management LLC acquired a new position in shares of First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter valued at $29,000. Vivaldi Capital Management LP increased its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock valued at $433,000 after purchasing an additional 1,741 shares during the period. Finally, Flputnam Investment Management Co. bought a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 4th quarter worth $230,000.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.